<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99282">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02074358</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-156</org_study_id>
    <secondary_id>2013-000646-18</secondary_id>
    <nct_id>NCT02074358</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects</brief_title>
  <official_title>A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of two 4-Factor PCC formulations on
      Apixaban pharmacodynamics in healthy adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Pharmacodynamic Measure: Endogenous thrombin potential (ETP) change from pre-prothrombin complex concentrate (PCC) baseline and Day 1 pre-Apixaban baseline</measure>
    <time_frame>Day 1-7</time_frame>
    <safety_issue>No</safety_issue>
    <description>ETP is a Thrombin Generation Assay (TGA) Parameter
Pre-PCC baseline is defined as the predose sample collected on Day 4, 3 hours after the Apixaban dose of each period
Day 1 pre-Apixaban baseline is defined as the predose sample collected on Day 1, prior to first Apixaban dose (0 hour)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Measures:Change from pre-PCC baseline and Day 1 pre-Apixaban baseline for other TGA parameters (Lag Time, Peak, Time to Peak and Velocity Index), PT, INR, aPTT and AXA</measure>
    <time_frame>Day 1-7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prothrombin time (PT), International Normalized Ratio (INR), activated partial thromboplastin time (aPTT) and activated anti-factor Xa activity (AXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments based on medical review of adverse event reports and the results of vital sign measurements, electrocardiograms, physical examinations, and clinical laboratory tests</measure>
    <time_frame>Up to 41 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The incidence of adverse events will be tabulated and reviewed for potential significance and clinical importance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose pharmacokinetic parameter: Maximum observed plasma concentration (Cmax) of Apixaban</measure>
    <time_frame>45 timepoints up to day 35</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose pharmacokinetic parameter: Time of maximum observed plasma concentration (Tmax) of Apixaban</measure>
    <time_frame>45 timepoints up to day 35</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose pharmacokinetic parameter: Area under the concentration-time curve in one dosing interval [AUC(0-12)] of Apixaban</measure>
    <time_frame>45 timepoints up to day 35</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose pharmacokinetic parameter: Area under the plasma concentration-time curve from time zero to 24 hours after dose administration [AUC(0-24)] of Apixaban</measure>
    <time_frame>45 timepoints up to day 35</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose pharmacokinetic parameter: Trough observed plasma concentration at the end of one dosing interval (12h) [Cmin] of Apixaban</measure>
    <time_frame>45 timepoints up to day 35</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple-dose pharmacokinetic parameter: Terminal elimination half-life (T-HALF) of Apixaban</measure>
    <time_frame>45 timepoints up to day 35</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Anticoagulation</condition>
  <arm_group>
    <arm_group_label>Treatment A: Apixaban + Placebo (Saline solution)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by Saline solution (placebo) 0 IU/kg  infusion for 30 min Intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: Apixaban + Cofact (4-Factor PCC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by a Cofact (4-Factor PCC) 50 IU/kg  infusion for 30 min Intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C: Apixaban + Beriplex P/N (4-Factor PCC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by a Beriplex P/N (4-Factor PCC) 50 IU/kg  infusion for 30 min Intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <arm_group_label>Treatment A: Apixaban + Placebo (Saline solution)</arm_group_label>
    <arm_group_label>Treatment B: Apixaban + Cofact (4-Factor PCC)</arm_group_label>
    <arm_group_label>Treatment C: Apixaban + Beriplex P/N (4-Factor PCC)</arm_group_label>
    <other_name>BMS-562247</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cofact (4-Factor PCC)</intervention_name>
    <arm_group_label>Treatment B: Apixaban + Cofact (4-Factor PCC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beriplex P/N (4-Factor PCC)</intervention_name>
    <arm_group_label>Treatment C: Apixaban + Beriplex P/N (4-Factor PCC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Saline solution)</intervention_name>
    <arm_group_label>Treatment A: Apixaban + Placebo (Saline solution)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Healthy subjects

          -  Body Mass Index (BMI) of 18 to 30 kg/m2

          -  Ages 18 to 45 years, including

          -  Women of childbearing potential (WOCBP) on acceptable contraception and with negative
             pregnancy test and not breastfeeding

        Exclusion Criteria:

          -  History or evidence of coagulopathy

          -  History or evidence of thrombosis such as deep vein thrombosis or other
             thromboembolic disease or having a first degree relative under 50 years of age with a
             history of thromboembolic disease

          -  Any significant acute or chronic medical illness or relevant trauma

          -  Any major surgery within 4 weeks of dosing (prior to dosing) or planned within 2
             weeks after completion of the study

          -  History of heavy menstrual bleeding that has produced anemia within the past 1 year

          -  Current symptomatic or recent gastrointestinal disease or surgery that could impact
             the absorption of study drug

          -  History of smoking within 1 month prior to dosing

          -  Recent history (within 6 months of dosing) of pregnancy

          -  Use of hormonal contraceptives

          -  Exposure to any investigational drug or placebo within 4 weeks of study drug
             administration

          -  Use of any agent, including but not limited to Aspirin, Nonsteroidal
             anti-inflammatory drugs (NSAIDs), Anticoagulants, Fish oil capsules, Gingko, etc,
             that are known to increase the potential for bleeding, within 2 weeks prior to dosing

          -  History of any severe drug allergy including allergy to Heparin or history of
             Heparin-induced thrombocytopenia, hypersensitivity to PCCs or Factor Xa inhibitors,
             or history of allergy to human blood plasma derived products; history of any adverse
             drug reaction to Anticoagulants or Antiplatelet agents that resulted in excessive
             bleeding requiring medical intervention
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 26, 2014</lastchanged_date>
  <firstreceived_date>February 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
